[A22-06] Abrocitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V
Last updated 07.07.2022
Project no.:
A22-06
Commission:
Commission awarded on 17.01.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Skin and hair
Moderate to severe atopic dermatitis in adults who are candidates for systemic therapy
Indication of considerable added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A22-60 | Abrocitinib (atopic dermatitis) - Addendum to Commission A22-06 | Commission completed |
| A24-45 | Abrocitinib (atopic dermatitis, adolescents 12 years and older) – Benefit assessment according to § 35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
07-07-2022 A G-BA decision was published.